UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
← catalyst calendarNCT06726720 · readout in 2,142 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
300estimated
Sites
52
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-16 | actual | When the study began enrolling |
| Primary completion | 2032-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
Primary outcomes
what the primary-completion date above is the date OFCohort A (resectable NSCLC)-Adjuvant rw DFS
measured 3 years
Cohort A (resectable NSCLC)- Peri-operative rw EFS
measured 3 years
Cohort B (unresectable NSCLC): median rwTFST
measured 3 years
Cohort C (metastatic NSCLC) rw TFST
measured 3 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed